ArticleFrontiers in medicine2026

Vedolizumab in biologic-naïve ulcerative colitis: a multicenter real-world evaluation of clinical benefits and exploratory inflammatory indices.

Hao Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.